Canaccord continues to see attractive entry point for Paratek

Canaccord analyst Dewey Steadman maintained a Buy rating and $25 price target on Paratek Pharmaceuticals following the release of the company's 10-K. In a research note to investors, Steadman says he is "encouraged" by the company's initial marketing efforts for Nuzyra and sees initial revenue guidance of $10M-$13M as achievable. As Nuzyra gains market acceptance over the coming quarters, Steadman says he likes the Paratek story and continues to see an attractive entry point for what could be one of the most compelling true antibacterial product launches in the past several years;


https://thefly.com/landingPageNews.php?id=2877677